Cleo Diagnostics Ltd is a biotechnology company specializing in the development of non-invasive, blood-based diagnostic tests designed to detect ovarian cancer. Its primary innovation is a pre-surgical triage test that measures specific biomarkers in patient serum, enabling clinicians to accurately differentiate between malignant ovarian cancer and benign gynecological conditions prior to surgical referral. This approach addresses a significant clinical need, as early and reliable detection of ovarian cancer remains a major challenge in women's healthcare, often impacting patient outcomes. Beyond product development, Cleo Diagnostics Ltd actively pursues the advancement and patenting of its proprietary technologies, with a strategic focus on both domestic and international regulatory pathways. With its medical devices positioned within the healthcare sector, the company contributes a critical tool for oncologists and gynecologists, aiming to improve diagnostic accuracy and reduce unnecessary invasive procedures. Cleo Diagnostics Ltd plays a meaningful role in the evolving landscape of cancer diagnostics by enhancing the standard of care and supporting better health outcomes for women globally.